Vertex Pharmaceuticals dominates cystic fibrosis therapies with TRIKAFTA/KAFTRIO generating $2.57 billion in Q4 2025 and ALYFTREK ramping to $380.1 million. The company posted strong free cash flow of $3.19 billion in 2025 and is expanding into pain, kidney disease, and gene-editing therapies.
Amgen shares have fallen 12.6% in three months despite relatively solid Q1 results, while Novo Nordisk maintains a 54.6% global GLP-1 market share. Both companies face pipeline competition and pricing pressures.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
A mouse study identified **TRPV4** as part of the neural feedback system that tells the brain when scratching has been sufficient. The findings suggest broadly blocking TRPV4 may not be the solution for chronic itch.
A February 2026 review analyzes strategies for kidney-targeted drug delivery systems, examining renal targeting mechanisms and nanocarrier platforms. The review highlights how functionalized nanoparticles can achieve enhanced renal specificity while addressing remaining translational challenges in the field.
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
New research suggests GLP-1 medications like Ozempic and Wegovy could help protect the heart after a heart attack by reopening tiny blood vessels that remain blocked even after major arteries are cleared during emergency treatment.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
University of Alberta researchers identified GlpG protease as a new drug target for treating antibiotic-resistant E. coli, which causes 250,000 UTI deaths annually. Inhibiting the protease prevented bacterial adhesion and biofilm formation in laboratory tests.
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07766707 |
Local and Systemic Inflammatory Bone Alterations Related to Dental Implant Survival. |
ACTIVE_NOT_RECRUITING | |
| NCT07760363 |
Pedal Pump Clinical Trial on Edema V1 |
RECRUITING | NA |
| NCT07757269 |
ABO/Rh Blood Group Phenotypes as Predictor of Treatment Outcomes in Diabetic Kidney Disease |
COMPLETED | |
| NCT07753681 |
Domestication and Implementation of the PEN-Plus Clinical Model in the Zambian Health System |
RECRUITING | |
| NCT07746219 |
The Clinical Research of Traditional Chinese Medicine Formula |
NOT_YET_RECRUITING | PHASE4 |
| NCT07740083 |
The Effect of Patient Empowerment Learning (With AI) About Itching in Hemodylasis Patients. |
ACTIVE_NOT_RECRUITING | NA |
| NCT07685886 |
MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE4 |
| NCT07678073 |
Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation |
RECRUITING | NA |
| NCT07668219 |
Efficacy of the Use of Real-time Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes and Stage 3 and 4 Chronic Kidney Disease. |
NOT_YET_RECRUITING | NA |
| NCT07662616 |
Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health |
NOT_YET_RECRUITING | EARLY_PHASE1 |
